The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The industry rank for Can Fite Biopharma's 9-Day RSI or its related term are showing as below:
CANF's 9-Day RSI is ranked worse than 64.44% of 1423
companies
in the Biotechnology industry
Industry Median: 45.82
vs CANF: 28.04
Can Fite Biopharma (AMEX:CANF) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Can Fite Biopharma 9-Day RSI Related Terms
CANF vs VRTX, REGN, ALNY: 9-Day RSI Comparison
For the Biotechnology subindustry, Can Fite Biopharma's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Can Fite Biopharma 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Can Fite Biopharma's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Can Fite Biopharma's 9-Day RSI falls into.
Can Fite Biopharma (AMEX:CANF) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Can Fite Biopharma (CANF) has a 9-Day RSI of 28.04 as of Jun. 28, 2026. According to the industry distribution chart, Can Fite Biopharma ranks #917 out of 1423 companies in the Biotechnology industry, placing it in the top 64.4%.
Is Can Fite Biopharma's 9-Day RSI too high?
Can Fite Biopharma's current 9-Day RSI is 28.04. The Biotechnology industry median 9-Day RSI is 45.82. Can Fite Biopharma's value of 28.04 is 38.8% below this industry median. Based on the distribution chart, Can Fite Biopharma ranks #917 out of 1423 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Can Fite Biopharma has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Can Fite Biopharma's 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Can Fite Biopharma ranks #917 out of 1423 companies for 9-Day RSI. This places Can Fite Biopharma in the lower half of its industry. The industry median 9-Day RSI is 45.82. Can Fite Biopharma's value of 28.04 is 38.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 45.82, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Can Fite Biopharma's current 9-Day RSI of 28.04 is 38.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 45.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Can Fite Biopharma's current 9-Day RSI is 28.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Can Fite Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Can Fite Biopharma (CANF) is currently considered Possible Value Trap. The stock's GF Value™ is $5.68, compared to a current price of $2.75 — trading 51.6% below its estimated fair value. The current 9-Day RSI is 28.04 and 38.8% below the Biotechnology industry median of 45.82. Can Fite Biopharma's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Can Fite Biopharma (CANF), the current 9-Day RSI is 28.04 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Can Fite Biopharma (CANF) Overvalued in 2026?
Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued.
The current stock price of $2.75 is trading 51.6% below its estimated GF Value™ of $5.68.
GuruFocus considers Can Fite Biopharma to be Possible Value Trap.
Key valuation signals for CANF:
9-Day RSI: 28.04
GF Value™: $5.68 vs. price of $2.75 (51.6% below fair value)
Industry Position: 38.8% below the Biotechnology median (#917 of 1423)
No single metric tells the full story. See the CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
55GF Score
Get the complete analysis for CANF
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CANF has been successfully added to your 